Longevity Capital Shows Up in Three Places at Once

Terme di Saturnia, the Tuscan thermal-spring destination spa long favored by advisors selling Italy wellness itineraries, has committed €15 million to expanding its longevity programming and upgrading facilities. The investment signals the property is moving beyond its traditional thermal-bathing identity toward the kind of structured medical-wellness offerings clients increasingly compare to Clinique La Prairie or Lanserhof.

For advisors, two practical points follow. First, expect construction and phased-access disruption at the property over the coming months — worth flagging before booking clients into affected areas. Second, this is a signal to start positioning Saturnia's expanded longevity offerings for 2027 arrivals, particularly with clients who've been asking about medical-wellness add-ons but balked at traveling farther afield. The capital commitment suggests the program will be substantive rather than a marketing refresh, so it's worth requesting details on scope and timeline directly from the property before promising specifics to clients.

Procter & Gamble's acquisition of supplements brand Thorne for $3.8 billion is a consumer-goods giant, not a niche wellness player, paying a premium to own a piece of the longevity category. That's a useful data point for advisors fielding skepticism from clients or colleagues who still treat longevity travel as a fad rather than durable demand.

The deal doesn't change any single itinerary or property, but it strengthens the commercial case for upselling longevity and medical-wellness retreats: the spending power behind this category is now validated by mainstream capital markets, not just wellness-industry advocacy. When a client hesitates on the cost of a longevity-focused program at a SHA Wellness or Clinique La Prairie, this is the kind of external proof point — real money, real acquirer, real premium — that reframes the conversation from indulgence to informed investment.

Montana's expanded "right to try" framework is moving toward its first drug reviews, a step that could position the state as an emerging domestic alternative to overseas longevity and experimental-treatment clinics. Clients who currently look to Clinique La Prairie in Switzerland or SHA Wellness in Spain for access to cutting-edge protocols may soon have a US-based option to consider — with obvious appeal for those wary of international medical travel or long-haul flights post-treatment.

It's early: this is regulatory groundwork, not a built-out destination-spa infrastructure, and advisors shouldn't treat it as booking-ready yet. But it's worth tracking as a genuinely new category rather than routine trend commentary — domestic medical tourism for experimental treatment is not something the US market has offered at scale before, and the first reviews moving forward is the signal to watch.